@docmrjaff

Chief Medical Officer, Peripheral Interventions; VP Med Affairs, Innovation & Technology @ Boston Scientific

 Boston, MA
bostonscientific.com
Joined April 2013
  • Tweets1.7K
  • Following314
  • Followers3K
396Media
DR MICHAEL R JAFF retweeted
Peter Pattison@bsc_io_eJul 23
Progress starts with the first case. We're excited to see the first #embolization and #Y90 procedures with the #TruSelect 2.6 #Microcatheter now underway across the U.S., bringing this latest innovation into clinical practice. Thank you Drs. Gary Siskin (@gsiskin), Chris Grilli, and Abhishek Kumar (@AbhiKumar47) for helping lead the way. #HandShapeableTip #TrackTorqueFlow
3
6
304
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular2 Nov 2025
Don’t miss the shift…visit the Boston Scientific suite at #VIVA25 to see the SEISMIQ difference 🔍 Learn more: bit.ly/4qBXEI3 #TheShiftIsSEISMIQ #IVLtherapy #ComingSoon
2
1
6
2,328
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular25 Jul 2025
Big News! The 544th—and final—patient has been enrolled in #HIPEITHO, a landmark RCT comparing EKOS + anticoagulation vs. anticoagulation alone in intermediate-high risk #PE. Thank you to our investigators, @PERTConsortium & @UnimedizinMainz. Learn more: bit.ly/44VQapx
1
14
4
60
15,484
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular22 Apr 2025
Excited to share that our dedicated investigators, @PERTConsortium & @UnimedizinMainz, have enrolled the 500th patient in #HIPEITHO! HI-PEITHO is the seminal global prospective multicenter RCT with primary endpoints that will be meaningful to all who manage patients with #PE
9
1
33
5,312
Clear evidence of BSC's commitment to patients with vascular diseases, the physicians who care for them, and innovation at the forefront.
Cat Jennings@bsc_vascular17 Sep 2024
Boston Scientific has officially closed the acquisition of @SilkRoadMed. We are excited to enhance our PI portfolio with innovative #TCAR tools and solutions to reduce stroke risk in patients with carotid artery disease during #vascularsurgery. Learn more: bit.ly/3zky0Sy
1
1
10
579
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular7 Aug 2024
#Fellows, join us to hear from a panel of world-class faculty as they give an in-depth educational experience on key interventional tools and techniques through case-based didactic presentations and hands-on training. Register now: cvent.me/DgkyER #MedEd #vasctwitter
2
1
12
1,711
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular18 Jun 2024
Very exciting news! #TCAR is at the forefront of innovation in #vascularmedicine enabling a clinically differentiated procedure to prevent stroke in patients with carotid artery disease. We look forward to @SilkRoadMed joining BSC & PI! #vascularsurgery
Boston Scientific@bostonsci18 Jun 2024
We’ve entered into a definitive agreement to acquire @silkroadmed, a med tech co. focused on stroke prevention in patients with carotid artery disease through the TCAR procedure. Upon close, we look forward to welcoming the Silk Road team! bit.ly/3KKCqEp
2
17
1,278
Join me for a LinkedIn Live discussion on the Impact of Real-World Evidence on PE Treatment Options with @AnasSafadi8 and Dr. Patrick Troy. Make sure to attend it today at 11 AM CST. linkedin.com/events/impactof…

LinkedIn Login, Sign in | LinkedIn

Login to LinkedIn to keep in touch with people you know, share ideas, and build your career.

linkedin.com
1
1
4
567
Thank you to all who made this incredible. Great to see you all! @bsc_pi @bsc_vascular
Cat Jennings@bsc_vascular10 Jun 2024
So grateful to the incredible faculty & attendees for an outstanding Vascular Master Class this past weekend. Your dedication to innovation and education is advancing patient care. Be sure to join us Sept 27-28 in Austin, TX for our next program!
1
1
4
659
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular30 May 2024
Don’t forget to register for our Vascular Master Class!
Cat Jennings@bsc_vascular6 May 2024
Join our expert faculty to discuss strategies, treatment algorithms, & tool selection through case-based didactic presentations & breakout sessions addressing PE & arterial disease management. Register now to be a part of the conversation: cvent.me/yVz1X2 *US-based only
1
5
884
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular6 May 2024
Join our expert faculty to discuss strategies, treatment algorithms, & tool selection through case-based didactic presentations & breakout sessions addressing PE & arterial disease management. Register now to be a part of the conversation: cvent.me/yVz1X2 *US-based only
1
1
3
1,323
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular15 Feb 2024
Proud to announce the 300th patient enrollment in #HIPEITHO! #HIPEITHO is the first of its kind RCT trial in #PE and continues to show BSC’s commitment to #EvidenceBasedMedicine. #EKOS #WhyWeEKOS
4
18
1,930
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular15 Nov 2023
Have you seen the results from the largest real-world and near real-time dataset evaluating advanced #PE therapies? Learn more about #REALPE here: bit.ly/REAL-PE #WhyWeEKOS #EvidenceBasedMedicine
1
11
1,000
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular31 Oct 2023
HAPPENING NOW | Reality Check: New Perspectives on Endovascular Strategies to Successfully Treat #PE w/ @monteleoneMD, @DKadiandodov, @roblookstein, Christopher Semder, MD and @docmrjaff #VIVA23 Learn more about #REALPE: bit.ly/REAL-PE
1
2
19
1,573
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular24 Oct 2023
LIVE | Reality Check: New Perspectives on Endovascular Strategies for #PE Treatment. Learn more about The REAL-PE Analysis: bit.ly/REAL-PE #MythShattered #WhyWeEKOS #TCT2023
5
21
1,648
Presented at #TCT2023 | REAL-PE, a study of over 2200 real-world #PE patients treated with #EKOS or FlowTriever—EKOS showed a statistically significant lower rate of major bleeding than patients treated with FlowTriever. Learn more: bit.ly/REAL-PE
2
22
56
6,994
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular23 Oct 2023
2
10
1,038
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular4 Oct 2023
#EKOS has excellent safety outcomes and is consistently proven, making it a first-line of #PE intervention. Learn more about how Dr. Bock uses EKOS as part of his toolkit to treat PE #WhyWeEKOS
Endovascular Today@EVToday4 Oct 2023
Jeremy S. Bock, MD, (@JeremySBockMD) talks about his experience with ultrasound-facilitated catheter-directed thrombolysis using the EKOS™ Endovascular System to treat pulmonary embolism. | #Sponsored by @bostonsci evtoday.com/articles/2023-se…

Treating Pulmonary Embolism With the EKOS™ Endovascular System: A Clinician’s Perspective -...

When imaging confirms the presence of a pulmonary embolism (PE), physicians must determine the best treatment approach for each patient by taking a ba

evtoday.com
3
8
1,756
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular28 Sep 2023
Thrilled to share that the first 750 patient data cut of the #ELEGANCERegistry was just published. This manuscript shows that differences exist in baseline disease characteristics by sex and race/ethnicity. #PAD #EvidenceBasedMedicine Learn more: bit.ly/3LGtccS

Implementing methods in the ELEGANCE registry to increase diversity in clinical research - PubMed

Analyses of data from the ELEGANCE registry show that differences exist in baseline disease characteristics by sex and race/ethnicity; these may be the result of other underlying factors, including...

pubmed.ncbi.nlm.nih.gov
5
12
2,081
DR MICHAEL R JAFF retweeted
Cat Jennings@bsc_vascular21 Sep 2023
Today we celebrate a milestone, 100K #PE patients have been treated with #EKOS. EKOS continues to be the most studied device in the PE space. With low lytic, low blood loss, and proven results, this is #WhyWeEKOS
4
20
2,105
Load more